[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354883-105":59,"doc-detail-354883-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ribosome-biogenesis-is-increased-in-hepatocellular-carcinoma-and-represents-a-potential-therapeutic-target","Ribosome biogenesis is increased in hepatocellular carcinoma and represents a potential therapeutic target","","Liver cancer remains a leading cause of cancer mortality, with many patients diagnosed at stages that limit effective interventions. A pan-cancer tissue microarray screening was performed to find cancer types exhibiting upregulated ribosome biogenesis responsive to nucleolar-targeting compounds. Liver cancer emerged as a candidate, and gene expression confirmed increased nucleolar factors linked to poor prognosis. In hepatocellular carcinoma cell lines, nucleolar proteins Treacle, UBF, and Fibrillarin were upregulated, rRNA production increased, and nucleolar targeting compounds sensitized cells while widening the therapeutic window over Sorafenib.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ribosome-biogenesis-is-increased-in-hepatocellular-carcinoma-and-represents-a-potential-therapeutic-target/354883/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ribosome-biogenesis-is-increased-in-hepatocellular-carcinoma-and-represents-a-potential-therapeutic-target/354883.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of the pan-cancer tissue microarray screening?","Question",{"text":112,"@type":113},"To identify cancer types with upregulated ribosome biogenesis that could be suitable for treatment with nucleolar-targeting compounds.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was hepatocellular carcinoma identified as a candidate?",{"text":117,"@type":113},"Gene expression analysis confirmed upregulated nucleolar factors that correlated with poor prognosis, and experiments in HCC models showed increased nucleolar activity and related rRNA production.",{"name":119,"@type":110,"acceptedAnswer":120},"How did nucleolar targeting compounds compare with Sorafenib?",{"text":121,"@type":113},"Nucleolar targeting compounds showed a broader therapeutic window than Sorafenib, which is a clinically approved targeted therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354883,1790196593,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","NAR Cancer, 2026, 8, zcaf058  \n[https://doi.org/10.1093/narcan/zcaf058](https://doi.org/10.1093/narcan/zcaf058)  \nCancer Gene Regulation, Chromatin, and Epigenetics  \nRibosome biogenesis is increased in hepatocellular carcinoma and represents a potential therapeutic target  \nSille Blangstrup Geisler†, Kezia Catharina Oxe†, Stavroula Boukoura, Ekaterina Dulina,  \n*  \nDorthe Helena Larsen   \nNucleolar Stress and Disease Group, Danish Cancer Institute, Copenhagen 2100, Denmark  \n∗ To whom correspondence should be addressed. Email: [dhl@cancer.dk](dhl@cancer.dk)[ ](dhl@cancer.dk)†The first two authors should be regarded as Joint First Authors.  \nAbstract  \nGlobally, liver cancer is the sixth most prevalent cancer type and the third leading cause of cancer-related deaths, making the need for improved treatment evident. We conducted a pan-cancer tissue microarray analysis to identify cancer types with upregulated ribosome biogenesis, potentially suitable for treatment with nucleolar-targeting compounds. Our screening identified liver cancer as a potential candidate. Gene expression analysis confirmed upregulation of nucleolar factors facilitating ribosome biogenesis that correlated with poor prognosis. In hepatocellular carcinoma (HCC) cell lines, constituting around 80% of liver cancer cases, we confirmed the upregulation of the nucleolar proteins Treacle, UBF, and Fibrillarin, involved in transcription and processing of ribosomal RNA (rRNA) . Measurements of rRNA also confirmed increased nucleolar activity. We treated the HCC cell lines with nucleolar-targeting compounds and observed increased sensitivity in the HCC cell lines. Notably, nucleolar targeting compounds demonstrated a broader therapeutic window than that observed for Sorafenib, a clinically approved targeted therapy. Furthermore, we investigated how nucleolar factors change during HCC stages and found a progressive increase in Treacle and Fibrillarin in advanced stages of HCC. Our results demonstrate aberrant nucleolar activity in HCC and propose targeting ribosome biogenesis as a therapeutic strategy to improve HCC patient outcomes.  \nGraphical abstract  \nIntroduction  \nHepatocellular carcinoma (HCC) is often diagnosed at advanced stages, making it challenging to treat and contribut-  \ning to a poor prognosis for HCC patients [1]. For those diagnosed early, treatments such as liver resection, local tumour destruction, or liver transplantation have positive outcomes  \nReceived: June 13, 2025. Revised: November 28, 2025. Accepted: December 17, 2025  \n© The Author(s) 2026. Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License  \n([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [journals.permissions@oup.com](journals.permissions@oup.com).  \n2 Geisler et al.  \n[1] . However, surgery is suitable for only 5–15% of all HCC patients, and recurrence remains a major issue, leading to a poor survival rate even for early-stage patients [1, 2] . Transarterial chemoembolization or the kinase inhibitor Sorafenibare approved treatment strategies for intermediate and advanced stages of HCC; however, both treatments result in only a modest increase in survival rates, and drug resistance to Sorafenib typically develops within 6 months [2] . Recently, advancements have been achieved with systemic therapy and immune checkpoint inhibitors, but the incidence-to-mortality ratio remains near one [3] . This highlights the importan","cbCainlR2JfTvTVV","https://ap.wps.com/l/cbCainlR2JfTvTVV","pdf",6712137,"English","# Abstract\n# Graphical abstract\n# Introduction","[{\"question\":\"What was the goal of the pan-cancer tissue microarray screening?\",\"answer\":\"To identify cancer types with upregulated ribosome biogenesis that could be suitable for treatment with nucleolar-targeting compounds.\"},{\"question\":\"How was hepatocellular carcinoma identified as a candidate?\",\"answer\":\"Gene expression analysis confirmed upregulated nucleolar factors that correlated with poor prognosis, and experiments in HCC models showed increased nucleolar activity and related rRNA production.\"},{\"question\":\"How did nucleolar targeting compounds compare with Sorafenib?\",\"answer\":\"Nucleolar targeting compounds showed a broader therapeutic window than Sorafenib, which is a clinically approved targeted therapy.\"}]","Ribosome biogenesis is increased in hepatocellular carcinoma and represents a potential therapeutic target | PDF",1790114580,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad75cfa080ac0a585eded9c486719111.webp",983,1272,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dc3bab9e8f49fbe40db5557a13f0034.webp",982,1270,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7757ac359eb51208720b80fd6f3d2d2.webp",981,1269,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f304a7ac7c8961ae22a46e552b1d13d.webp",980,1268]